#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14504	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2493	715.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1892	1892	T	907	T,C	905,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14504	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2493	715.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1626	1626	C	900	C,A	899,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14504	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2493	715.6	0	HET	.	.	.	C207T	.	207	207	C	649	649	C	873	C,T	671,202	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24738	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4099	751.7	0	.	n	.	0	T695C	SNP	695	695	T	1258	1258	C	936	C,A,T	933,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24738	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4099	751.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2534	2534	C	883	C,T,A	880,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24738	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4099	751.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2608	2608	A	837	A,C	836,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24738	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4099	751.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3160	3160	C	891	C,G,A	887,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	2170	folP	855	855	100.0	folP.l15.c4.ctg.1	2138	126.6	1	SNP	p	R229S	0	.	.	685	687	CGC	1313	1315	CGC	211;212;213	C;G;C	211;212;213	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5230	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3777	172.5	1	SNP	p	S91F	0	.	.	271	273	TCC	767	769	TCC	205;205;205	T;C;C	203;202;203	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5230	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3777	172.5	1	SNP	p	D95N	0	.	.	283	285	GAC	779	781	GAC	215;213;214	G,T;A,G;C	211,2;209,1;211	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5230	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3777	172.5	1	SNP	p	D95G	0	.	.	283	285	GAC	779	781	GAC	215;213;214	G,T;A,G;C	211,2;209,1;211	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1858	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1899	122.0	0	.	p	.	0	D79N	NONSYN	235	237	GAT	883	885	AAT	192;192;193	A;A;T	192;191;192	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1858	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1899	122.0	1	SNP	p	G45D	0	.	.	133	135	GGC	781	783	GGC	210;210;210	G;G;C	210;210;210	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1082	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1475	91.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4752	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3388	174.7	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2357	2359	ATT	249;247;240	A;T;T	248;247;240	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4752	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3388	174.7	1	SNP	p	D86N	0	.	.	256	258	GAC	827	829	GAC	203;200;201	G;A;C	203;200;201	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4752	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3388	174.7	1	SNP	p	S87I	0	.	.	259	261	AGT	830	832	AGT	199;201;201	A,G;G;T	198,1;201;201	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4752	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3388	174.7	1	SNP	p	S87R	0	.	.	259	261	AGT	830	832	AGT	199;201;201	A,G;G;T	198,1;201;201	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4752	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3388	174.7	1	SNP	p	S87W	0	.	.	259	261	AGT	830	832	AGT	199;201;201	A,G;G;T	198,1;201;201	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4752	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3388	174.7	1	SNP	p	S88P	0	.	.	262	264	TCC	833	835	TCC	201;203;207	T;C;C,A	201;203;206,1	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4318	parE	1986	1986	99.9	parE.l15.c4.ctg.1	3132	171.8	0	.	p	.	0	V89A	NONSYN	265	267	GTC	823	825	GCC	223;222;220	G;C,T;C	223;221,1;220	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4318	parE	1986	1986	99.9	parE.l15.c4.ctg.1	3132	171.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1786	1788	GGC	242;243;241	G;G,T;C,A	242;242,1;240,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.15.001	penA.15.001	1	1	27	3862	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2854	168.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1482	1484	GCA	210;211;210	G;C;A	210;211;210	penA.15.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3862	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2854	168.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1485	1487	ATC	210;211;210	A;T;C	210;211;210	penA.15.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3862	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2854	168.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1497	1499	GTG	212;216;216	G;T,C,A;G	212;214,1,1;216	penA.15.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3862	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2854	168.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1497	1499	GTG	212;216;216	G;T,C,A;G	212;214,1,1;216	penA.15.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3862	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2854	168.4	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1998	2000	ACC	225;224;223	A,G;C;C	224,1;224;223	penA.15.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3862	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2854	168.4	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2052	2054	GCG	197;196;193	G;C;G,C	197;196;191,1	penA.15.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3862	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2854	168.4	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2052	2054	GCG	197;196;193	G;C;G,C	197;196;191,1	penA.15.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3862	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2854	168.4	1	SNP	p	G542S	0	.	.	1624	1626	GGC	2175	2177	GGC	201;200;201	G;G;C	200;199;200	penA.15.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3862	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2854	168.4	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2184	2186	GGC	207;209;211	G,C;G;C	206,1;209;211	penA.15.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3862	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2854	168.4	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2202	2204	CCG	225;224;222	C,G;C;G,C	222,3;224;220,2	penA.15.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5342	ponA	2397	2397	99.92	ponA.l15.c4.ctg.1	3679	180.9	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1925	1927	CTG	176;179;179	C;T;G	175;178;179	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2462	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2359	130.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	827	827	C	172	C	172	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	T89S	NONSYN	265	267	ACC	911	913	AGC	264;263;261	A;G;C	264;263;261	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	.	MULTIPLE	358	359	AA	1003	1004	CG	205;204	C,T;G	204,1;204	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	.	MULTIPLE	361	362	GA	1006	1008	CAG	206;200;199	C;A,C;G	206;199,1;199	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	N122K	NONSYN	364	366	AAC	1010	1012	AAA	201;201;204	A;A,T,G;A,G	201;199,1,1;203,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	1037	1039	TAT	213;212;207	T,C;A;T,G	212,1;212;206,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	N134E	NONSYN	400	402	AAT	1046	1048	GAG	199;197;204	G,A,C;A,G;G	196,2,1;196,1;204	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	V135F	NONSYN	403	405	GTG	1049	1051	TTT	202;199;198	T,C;T;T	201,1;199;198	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	G140K	NONSYN	418	420	GGA	1064	1066	AAA	205;204;202	A;A;A	205;204;202	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	K143E	NONSYN	427	429	AAA	1073	1075	GAA	207;207;206	G;A;A,C	207;207;205,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1097	1099	GCA	224;221;221	G,C;C;A	221,2;221;221	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	1205	1207	CAA	263;265;263	C;A,G,T;A,C	263;263,1,1;262,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	N189S	NONSYN	565	567	AAC	1211	1213	AGC	258;259;260	A;G;C	258;259;260	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	T213L	NONSYN	637	639	ACA	1283	1285	TTA	243;243;243	T;T;A	243;243;243	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	A244V	NONSYN	730	732	GCA	1376	1378	GTA	239;240;239	G;T;A	239;240;239	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1403	1405	CAA	195;194;196	C;A;A,C	195;194;195,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	.	INDELS	760	762	ACA	1407	1411	ATCAA	195;193;190;189;188	A;T;C;A;A	195;193;190;189;188	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	.	INDELS	763	764	TG	1414	1416	AGT	187;186;180	A;G;T	187;186;180	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1421	1423	GAT	181;181;182	G;A,C;T	181;180,1;182	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	V270A	NONSYN	808	810	GTA	1460	1462	GCG	193;191;193	G;C;G	193;191;193	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1529	1531	AGT	217;215;213	A;G,T;T	217;213,2;213	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	1	SNP	p	G120K	1	.	.	358	360	AAG	1003	1005	CGG	205;204;205	C,T;G;G,A	204,1;204;204,1	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	1	SNP	p	D121N	0	.	.	361	363	GAC	1006	1009	CGC	206;199;200	C;G;C	206;199;200	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2768	porB1b	1041	1041	96.18	porB1b.l6.c30.ctg.1	2281	149.9	1	SNP	p	A121D	1	.	.	361	363	GAC	1006	1009	CGC	206;199;200	C;G;C	206;199;200	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9762	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5336	228.0	0	.	p	.	0	R364W	NONSYN	1090	1092	CGG	1707	1709	TGG	271;267;266	T,C;G;G,C	269,2;267;265,1	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9762	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5336	228.0	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2274	2276	CAT	251;252;254	C,G;A;T	250,1;252;254	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1526	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1324	142.4	1	SNP	p	V57M	0	.	.	169	171	GTG	675	677	GTG	271;272;268	G;T,C;G,C,A	271;271,1;266,1,1	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
